Edition:
United States

Grifols SA (GRLSbn.MC)

GRLSbn.MC on Madrid SE C.A.T.S.

17.06EUR
25 Apr 2019
Change (% chg)

€0.06 (+0.35%)
Prev Close
€17.00
Open
€17.26
Day's High
€17.26
Day's Low
€17.00
Volume
77,151
Avg. Vol
122,795
52-wk High
€21.30
52-wk Low
€15.60

Latest Key Developments (Source: Significant Developments)

Rigel Pharmaceuticals Enters Collaboration And License Agreement With Grifols S.A. To Commercialize Fostamatinib In Europe
Wednesday, 23 Jan 2019 07:30am EST 

Jan 23 (Reuters) - Grifols SA ::RIGEL PHARMACEUTICALS ENTERS COLLABORATION AND LICENSE AGREEMENT WITH GRIFOLS, S.A. TO COMMERCIALIZE FOSTAMATINIB IN EUROPE.RIGEL PHARMACEUTICALS - TO RECEIVE AN UPFRONT PAYMENT OF $30 MILLION, WITH POTENTIAL FOR $297.5 MILLION IN TOTAL REGULATORY AND COMMERCIAL MILESTONES.RIGEL PHARMACEUTICALS INC - GRIFOLS GAINS EXCLUSIVE RIGHTS TO FOSTAMATINIB IN ALL POTENTIAL INDICATIONS IN EUROPE AND TURKEY.RIGEL PHARMACEUTICALS INC - TO RECEIVE STEPPED ROYALTY PAYMENTS REACHING 30% OF NET SALES OF FOSTAMATINIB.RIGEL PHARMACEUTICALS - ANTICIPATES A DECISION FROM EMA'S COMMITTEE ON HUMAN MEDICINAL PRODUCTS BY Q4 OF 2019 AND POTENTIAL EUROPEAN APPROVAL BY 2019 END.  Full Article

Grifols Receives FDA Approval Of Erytra Eflexis
Tuesday, 8 Jan 2019 07:38am EST 

Jan 8 (Reuters) - Grifols SA ::GRIFOLS RECEIVES FDA APPROVAL OF ERYTRA EFLEXIS®, THE LATEST ADVANCEMENT IN SCALABLE BLOOD TYPING SOLUTIONS.  Full Article

Grifols Sells Biotest And Haema To Scranton For $537 Mln
Monday, 31 Dec 2018 08:02am EST 

Dec 31 (Reuters) - Grifols SA ::SAYS SELLS BIOTEST US CORPORATION AND HAEMA AG TO SCRANTON ENTERPRISES BV FOR $537 MILLION.WILL HAVE CALL OPTION OVER ALL SHARES OF COMPANIES SOLD TO SCRANTON.  Full Article

Medcom Tech Says Grifols To Invest In Its Diagnostic Unit MedcomAdvance
Thursday, 20 Dec 2018 11:51am EST 

Dec 20 (Reuters) - Medcom Tech SA ::SAYS ITS UNIT MEDCOMADVANCE SIGNS AGREEMENT WITH GRIFOLS TO TAKE FORWARD ITS CLINICAL DIAGNOSIS TECHNOLOGY.GRIFOLS TO ENTER SHAREHOLDING OF 51 PERCENT IN MEDCOMADVANCE WITH INVESTMENT OF 10 MILLION EUROS.  Full Article

Grifols 9-Month Net Profit Up 8.5 Pct YoY
Monday, 5 Nov 2018 02:27am EST 

Nov 5 (Reuters) - Grifols SA ::9-MONTH NET PROFIT 468.3 MILLION EUROS VERSUS 431.8 MILLION EUROS YEAR AGO.9-MONTH EBITDA 939.4 MILLION EUROS VERSUS 960.9 MILLION EUROS YEAR AGO.9-MONTH NET REVENUE 3.26 BILLION EUROS VERSUS 3.25 BILLION EUROS YEAR AGO.9-MONTH RESEARCH AND DEVELOPMENT NET INVESTMENT 209.9 MILLION EUROS VERSUS 201.6 MILLION EUROS YEAR AGO.  Full Article

Grifols Obtains 85 Mln Euro Loan From EIB
Friday, 7 Sep 2018 05:47am EDT 

Sept 7 (Reuters) - Grifols SA ::SAYS OBTAINED NEW LONG-TERM LOAN WITH EUROPEAN INVESTMENT BANK (EIB) TOTALING 85 MILLION EUROS.SAYS CONDITIONS INCLUDE FIXED INTEREST RATE OVER 10 YEARS AND TWO-YEAR GRACE PERIOD.  Full Article

Grifols Receives FDA Approval For New Manufacturing Facility For Production Of Recombinant Proteins
Thursday, 16 Aug 2018 08:00am EDT 

Aug 16 (Reuters) - Grifols SA ::GRIFOLS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE NEW CONSOLIDATED MANUFACTURING FACILITY (CMF) FOR PRODUCTION OF RECOMBINANT PROTEINS.  Full Article

Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S.
Monday, 5 Mar 2018 09:00am EST 

March 5 (Reuters) - Grifols Sa ::GRIFOLS - ANNOUNCES NEW AGREEMENT WITH HENRY SCHEIN TO DISTRIBUTE NORMAL SALINE SOLUTION IN THE U.S..GRIFOLS - IN 2018, GRIFOLS WILL CONTINUE EXPANSION OF ITS CAPACITY IN ITS INDUSTRIAL COMPLEX IN BARCELONA.GRIFOLS - ‍EXPANSION INCLUDES 2 NEW PRODUCTION LINES OF IV SOLUTIONS, ENABLING BARCELONA PLANT TO ADD PRODUCTION CAPACITY BY 20 MILLION UNITS​.  Full Article

Grifols FY Net Profit Up At 662.7 Mln Euros
Wednesday, 28 Feb 2018 02:27am EST 

Feb 28 (Reuters) - Grifols ::FY NET SALES 4.32 BILLION EUROS VERSUS 4.05 BILLION EUROS YEAR AGO.FY NET PROFIT 662.7 MILLION EUROS VERSUS 545.5 MILLION EUROS YEAR AGO.  Full Article

Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment
Tuesday, 6 Feb 2018 09:45am EST 

Feb 6 (Reuters) - Grifols SA ::GRIFOLS HYPERRAB® (RABIES IMMUNE GLOBULIN HUMAN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION.  Full Article

Photo

Spain's Grifols, China's Shanghai RAAS form strategic alliance

Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China.